Babich Olga, Dyshlyuk Lyubov, Prosekov Alexander, Noskova Svetlana, Ivina Oksana, Pavsky Valery, Ivanova Svetlana, Bulgakova Olga
Institute of Living Systems, Immanuel Kant Baltic Federal University, A. Nevskogo Street 14, Kaliningrad 236016, Russia.
Research Institute of Biotechnology, Kemerovo State University, Krasnaya Street 6, Kemerovo 650043, Russia.
Pharmaceuticals (Basel). 2020 Apr 9;13(4):63. doi: 10.3390/ph13040063.
The treatment of classical phenylketonuria is currently represented by many new methods of disease management. A promising method is the use of the enzyme L-phenylalanine ammonia-lyase (PAL) in various forms. The widespread use of enzyme preparations in therapy is limited by a lack of understanding of the mechanisms and systems of the targeted transport of PAL into certain organs and tissues as a result of the incorporation of a drug into the carrier. To ensure the stability of enzymes during the delivery process, encapsulation is preferable, which, as a rule, ensures the preservation of the qualitative characteristics of the enzymes orally applied to the environmental effects of the gastrointestinal tract (acidity, temperature, oxidation, etc.). Capsule preparations showed sufficient stability in the model gastric fluids and sustained release of the drug in the simulated intestinal fluid. Currently, there is a wide range of polymers used for encapsulation. The use of natural sources in the production technology of capsule systems improves bioavailability, controls the release, and prolongs the half-life of active substances. The advantage of this method is that the used enzyme is completely protected by the cell membranes of the capsules, which preserve its stability in the aggressive environment of the gastrointestinal tract. Capsules were obtained on the basis of compositions of hydrocolloids of plant origin. The potential of the developed capsules for targeted delivery of the enzyme preparation was studied. The degradation of the encapsulated form of the PAL enzyme preparation was studied in vitro in model bio-relevant media simulating the gastric and intestinal environment. The dynamics of the breakdown of the capsule shell allow us to expect that the release of L-phenylalanine ammonia-lyase from capsules based on plant hydrocolloids will occur no earlier than reaching the upper intestines, where the interaction with the protein components of the consumed food products to neutralize phenylalanine should occur.
目前,经典型苯丙酮尿症的治疗有许多新的疾病管理方法。一种有前景的方法是使用各种形式的L-苯丙氨酸解氨酶(PAL)。由于药物与载体结合,对PAL靶向转运至特定器官和组织的机制及系统缺乏了解,限制了酶制剂在治疗中的广泛应用。为确保酶在递送过程中的稳定性,包封是优选的,通常来说,包封可确保口服应用的酶的定性特征在胃肠道环境影响(酸度、温度、氧化等)下得以保留。胶囊制剂在模拟胃液中显示出足够的稳定性,并在模拟肠液中持续释放药物。目前,有多种聚合物用于包封。在胶囊系统生产技术中使用天然来源可提高生物利用度、控制释放并延长活性物质的半衰期。该方法的优点是所用酶完全受到胶囊细胞膜的保护,从而在胃肠道的侵蚀性环境中保持其稳定性。基于植物来源的水胶体组合物制备了胶囊。研究了所开发的胶囊对酶制剂进行靶向递送的潜力。在模拟胃和肠环境的模型生物相关介质中体外研究了PAL酶制剂包封形式的降解。胶囊壳的降解动态使我们预期,基于植物水胶体的胶囊中L-苯丙氨酸解氨酶的释放不会早于到达上肠道时发生,在上肠道中应会与所摄入食品的蛋白质成分相互作用以中和苯丙氨酸。